Skip to content
Press Releases
Filter Releases
 
Press Releases
Jun 1, 2017
SOUTH SAN FRANCISCO, Calif., June 1, 2017 /PRNewswire/ -- Veracyte, Inc. (NASDAQ: VCYT) today announced that Bonnie H. Anderson, chairman and chief executive officer, will present at the William Blair 2017 Growth Stock Conference on Thursday, June 15, 2017 at 8:00 a.m. CT in Chicago, IL. The live webcast from the William Blair conference and...
PDF
May 23, 2017
SOUTH SAN FRANCISCO, Calif., May 23, 2017 /PRNewswire/ -- Veracyte, Inc. (NASDAQ: VCYT), a genomic diagnostics company focused on reducing unnecessary surgeries and healthcare costs by resolving diagnostic uncertainty, announced today that pivotal clinical validation data demonstrating the performance of its Envisia Genomic Classifier were presente...
PDF
May 18, 2017
SOUTH SAN FRANCISCO, Calif., May 18, 2017 /PRNewswire/ --  Veracyte, Inc. (NASDAQ: VCYT), a genomic diagnostics company focused on reducing unnecessary surgeries and healthcare costs by resolving diagnostic uncertainty, today announced that Anthem, Inc., an independent Blues plan and one of the nation's largest health benefits companies, has issued...
PDF
May 11, 2017
SOUTH SAN FRANCISCO, Calif., May 11, 2017 /PRNewswire/ -- Veracyte, Inc. (NASDAQ: VCYT), a genomic diagnostics company focused on reducing unnecessary surgeries and healthcare costs by resolving diagnostic uncertainty, announced that data demonstrating the cost-effectiveness of the Percepta Bronchial Genomic Classifier were published for the first ...
PDF
May 10, 2017
SOUTH SAN FRANCISCO, Calif., May 10, 2017 /PRNewswire/ -- Veracyte, Inc. (NASDAQ: VCYT), a genomic diagnostics company focused on reducing unnecessary surgeries and healthcare costs by resolving diagnostic uncertainty, today announced that data from multiple studies supporting use of the company's genomic classifiers to improve the diagnosis of lun...
PDF
May 8, 2017
SOUTH SAN FRANCISCO, Calif., May 8, 2017 /PRNewswire/ -- Veracyte, Inc. (NASDAQ: VCYT), a genomic diagnostics company focused on reducing unnecessary surgeries and healthcare costs by resolving diagnostic uncertainty, today announced new data from two studies demonstrating that use of the Afirma Gene Expression Classifier (GEC) significantly reduce...
PDF
May 4, 2017
SOUTH SAN FRANCISCO, Calif., May 4, 2017 /PRNewswire/ -- Veracyte, Inc. (NASDAQ: VCYT), a genomic diagnostics company focused on reducing unnecessary surgeries and healthcare costs by resolving diagnostic uncertainty, today announced data from a pivotal clinical validation study of its Afirma Genomic Sequencing Classifier (GSC). The data suggest th...
PDF
May 3, 2017
SOUTH SAN FRANCISCO, Calif., May 3, 2017 /PRNewswire/ -- Revenue was $16.4 Million, a 21% Growth Over Prior Year Cash Burn was $8.3 Million, a 28% Improvement Over Prior Year Conference Call and Webcast Today at 4:30 p.m. ET Veracyte, Inc. (NASDAQ: VCYT) today announced financial results and business progress for the fir...
PDF
Apr 26, 2017
SOUTH SAN FRANCISCO, Calif., April 26, 2017 /PRNewswire/ -- Veracyte, Inc. (NASDAQ: VCYT), a genomic diagnostics company focused on reducing unnecessary surgeries and healthcare costs by resolving diagnostic uncertainty, today announced that new data demonstrating the strong performance of the Afirma Gene Expression Classifier (GEC) in thyroid canc...
PDF
Apr 19, 2017
SOUTH SAN FRANCISCO, Calif., April 19, 2017 /PRNewswire/ -- Veracyte, Inc. (NASDAQ: VCYT) today announced that it will report its first quarter 2017 financial results after close of market on Wednesday, May 3, 2017. Following the announcement, Veracyte's management will host a live conference call and webcast at 4:30 p.m. Eastern Time to discuss th...
PDF
Page: First Previous
...
Next Last